Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Head and Neck Cancer

  Free Subscription


15.09.2025

4 Am J Surg
1 Br J Oral Maxillofac Surg
1 Dis Esophagus
1 Head Neck
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
3 Ophthalmic Plast Reconstr Surg
10 Oral Oncol
1 PLoS One
1 Radiother Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Surg

  1. ZHANG G, Chen Y, Jin D, Sui Z, et al
    Postoperative survival evaluation of patients with Siewert II adenocarcinoma of esophagogastric junction: a population-based study.
    Am J Surg. 2025;248:116536.
    PubMed         Abstract available

  2. DONE JZ, Helbing A, Stemme R, Foote D, et al
    Higher Distressed Communities Index is associated with more aggressive features in papillary thyroid cancer.
    Am J Surg. 2025;248:116520.
    PubMed         Abstract available

  3. MONREAL AJ, Eze AN, Thomas SM, Johnson KS, et al
    Exploring actionable targets to address disparities in thyroid cancer survival: A study of patients with aggressive variants of papillary thyroid cancer.
    Am J Surg. 2025;248:116428.
    PubMed         Abstract available

  4. LAURIE BD, Thomas E, Nguyen H, Ryan S, et al
    FDG-avid thyroid nodules are at a significantly increased risk of malignancy.
    Am J Surg. 2025;248:116400.
    PubMed         Abstract available


    Br J Oral Maxillofac Surg

  5. MERCHANT Y, Shetty SS
    Comment on: Lateralised T3/T4N0 oral squamous cell carcinoma. Is contralateral elective neck dissection or neck radiotherapy indicated? A multicentre retrospective study.
    Br J Oral Maxillofac Surg. 2025 Aug 23:S0266-4356(25)00209.
    PubMed        


    Dis Esophagus

  6. MATSUDA S, Wijnhoven B, Lordick F, Bhandari P, et al
    Quality indicator survey of clinical practice guidelines for esophagogastric junction cancer 2023.
    Dis Esophagus. 2025;38:doaf071.
    PubMed         Abstract available


    Head Neck

  7. ISHIHARA H, Asahi Y, Kuroki M, Saijo K, et al
    Prognosis After Discontinued Treatment due to Immune-Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
    Head Neck. 2025 Sep 12. doi: 10.1002/hed.70043.
    PubMed         Abstract available


    Int J Cancer

  8. AMURE MT, Madathil SA, Laprise C, Rousseau MC, et al
    Oral co-infection with multiple alpha-human papillomavirus and head and neck cancer risk.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70124.
    PubMed         Abstract available

  9. DENNIS CD, Cohen DJ, Debnath K, Schwartz N, et al
    24R,25(OH)(2)D(3) regulates tumorigenesis in estrogen sensitive laryngeal cancer cells via membrane-associated receptor complexes in ER+ and ER- cells.
    Int J Cancer. 2025 Sep 8. doi: 10.1002/ijc.70141.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  10. TANDON S, Ahlawat P, Mahajan S, Bellige A, et al
    Depth of Invasion as an Independent Indication for Postoperative Radiation Therapy in Oral Tongue Squamous Cell Carcinoma.
    Int J Radiat Oncol Biol Phys. 2025;123:442-451.
    PubMed         Abstract available


    J Clin Oncol

  11. LU Z, Yan K, Sheng Y, Rukonge PA, et al
    Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma.
    J Clin Oncol. 2025 Sep 11:JCO2501053. doi: 10.1200/JCO-25-01053.
    PubMed        

  12. LU Z, Du W, Jiao X, Wang Y, et al
    Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".
    J Clin Oncol. 2025 Sep 11:JCO2501535. doi: 10.1200/JCO-25-01535.
    PubMed        


    Ophthalmic Plast Reconstr Surg

  13. CRUZ AAVE, Albano de Guimaraes J, Brassaloti SS, Lima RS, et al
    The Role of Perforator Island Flaps for the Reconstruction of Midfacial and Periorbital Large and Deep Defects.
    Ophthalmic Plast Reconstr Surg. 2025;41:593-598.
    PubMed         Abstract available

  14. LIU D, Oh A, Shirriff A, Rapola EW, et al
    Intralesional Bleomycin Palliation: An Option for Nonoperative Sebaceous Cell Carcinoma of the Eyelid.
    Ophthalmic Plast Reconstr Surg. 2025 May 6. doi: 10.1097/IOP.0000000000002949.
    PubMed         Abstract available

  15. KOTHARI AN, Wang DD, Menon VA, Sullivan TJ, et al
    An Unusual Case of Medial Canthal Angioleiomyoma.
    Ophthalmic Plast Reconstr Surg. 2025;41:e148-e150.
    PubMed         Abstract available


    Oral Oncol

  16. LUO L, Lu C, Feng H
    Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
    Oral Oncol. 2025;169:107681.
    PubMed        

  17. VENKATACHALAM DK, Kanimozhi K
    Letter to the Editor "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107679.
    PubMed        

  18. MISRA SR, Das R
    The imperative of careful selection and novel strategies: Comment on Mrosk et al.'s outcomes of primary chemoradiation for advanced oral cancer.
    Oral Oncol. 2025;169:107676.
    PubMed        

  19. KUMAR GN, Sangeetha S
    Comment on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025 Sep 8:107666. doi: 10.1016/j.oraloncology.2025.107666.
    PubMed        

  20. XIAO X, Liu T, Song Y, Lu M, et al
    Evaluation on the prognostic significance of cervical occult metastasis in cN0 glottic laryngeal cancer.
    Oral Oncol. 2025;169:107648.
    PubMed        

  21. ZHANG D, Zhang J, Cai M
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107660.
    PubMed        

  22. ZHANG D, Zhang P, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107661.
    PubMed        

  23. DUAN Y
    Letter to the Editor: Oral cancer screening in India: A secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107657.
    PubMed        

  24. ZHANG D, Zhou Y, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107659.
    PubMed        

  25. MISRA SR, Das R
    Critical appraisal of "Oral cancer screening in India: A secondary analysis of disparities using national family health survey data".
    Oral Oncol. 2025;169:107653.
    PubMed        


    PLoS One

  26. DENG M, Lin Y, Yan L, Fei Z, et al
    Global burden of head and neck cancer from 1990 to 2021: A comprehensive analysis and projections to 2030 based on the global burden of disease study 2021.
    PLoS One. 2025;20:e0330805.
    PubMed         Abstract available


    Radiother Oncol

  27. LIU Y, Su Y, Peng J, Zhang W, et al
    A multidimensional deep ensemble learning model predicts pathological response and outcomes in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy from pretreatment CT imaging: A multicenter study.
    Radiother Oncol. 2025 Sep 10:111133. doi: 10.1016/j.radonc.2025.111133.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.